Expert panelists discuss the essential role of primary care in early skin cancer detection, balancing clinical judgment with emerging AI artificial intelligence tools, and more.

Clevenger reviews survey findings behind the recent report "The Agitation Blindspot in Alzheimer’s Care."

A regular focus on mental heatlh during follow-ups with patients who have atopic dermatitis can be integrated simply with a few thoughtful questions.

Mental health apps show high initial uptake but moderate adherence, revealing key factors for improving user retention in clinical trials.

Novo Nordisk submits an FDA application for semaglutide 7.2 mg for chronic weight management, supported by STEP UP trial data showing greater weight loss.

Panelists discuss how elinzanetant offers a safe, effective nonhormonal option for managing VMS in women receiving endocrine therapy for breast cancer.

Panelists discuss how elinzanetant demonstrates strong efficacy and safety across trials, reinforcing neurokinin modulation as a viable core treatment for VMS.

Otsuka seeks FDA approval for centanafadine, a novel ADHD treatment showing significant efficacy and safety in pivotal trials for all age groups.

Novartis's Itvisma gains FDA approval as the first intrathecal gene therapy for spinal muscular atrophy, promising improved motor function and independence.

Primary care is the ideal setting for management of atopic dermatitis, but certain scenarios, both physical and psychological, call for expert referral.

J&J halts phase 2b AuTonomy trial after anti-tau antibody posdinemab fails to slow clinical decline, marking another setback for tau-targeting therapeutics.